All-round show: Biocon net rises 12%

India’s largest biotechnology company Biocon on Thursday posted a 12.5% year-on-year rise in net profit at Rs. 79 crore for the quarter ended June, 2012 against Rs. 70 crore a year ago on the back of healthy growth in branded formulations, contract research and biopharmaceuticals businesses.

India’s largest biotechnology company Biocon on Thursday posted a 12.5% year-on-year rise in net profit at Rs. 79 crore for the quarter ended June, 2012 against Rs. 70 crore a year ago on the back of healthy growth in branded formulations, contract research and biopharmaceuticals businesses.

HT Image

“We have seen strong performances across all our business verticals,” said Kiran Mazumdar-Shaw, chairman and managing director, Biocon.

Income from biopharmaceuticals business grew 23% to Rs. 368 crore during the quarter from Rs. 299 crore a year ago. Income from branded formulations jumped 52% to Rs. 86 crore from Rs. 57 crore in the same quarter of the previous fiscal year led by oncology, diabetology and comprehensive care. Contract research business grew 40% to Rs. 123 crore from Rs. 88 crore.

Biocon’s shares fell 5% to Rs. 239 on the BSE on Thursday.